Colfax Plans To Split To Form Separate Medtech And Fabtech Companies

The yet-to-be-named medtech company will focus on orthopedic implants and bracing and recovery devices.

A king and a queen stand in isolation at different ends of a chessboard.
• Source: shutterstock.com

Colfax Corporation plans to split its fabrication technology and specialty medical technology businesses into two independent publicly traded companies by the first quarter of 2022.

“Our intention is to set up both companies with effective capital structures that are aligned with their different strategies,” Colfax CEO Matthew Trerotola said during a 4 March conference call...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

Medtronic To Spin Out Diabetes Unit As New Products Solidify Turn-Around Story

 
• By 

Medtronic’s diabetes spin-out – a process likely to run up to 18 months and involve 20% IPO followed by a split-off for Medtronic shareholders – will allow firm to focus on higher-margin devices.

FDA Halts Acceptance Of Chinese Lab Data Due To Accuracy Issues

 
• By 

The FDA has stopped accepting data from two Chinese labs due to accuracy issues. Mid-Link and SDWH have been flagged for potentially falsified results and other misconduct. This decision, which follows months of discussions and warnings, emphasizes the FDA's commitment to ensuring data integrity in medical device submissions.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.